Bicycle Therapeutics plc ADR (BCYC)
NASDAQ: BCYCHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BCYC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $203.27M
- EPS (TTM)
- -$2.03
- Dividend yield
- None
- 52-week range
- 2.85 – 7.83
- Day range
- 2.85 – 3.00
- Volume / Avg
- 1.02M / 444.72K
- Beta
- —
- Shares outstanding
- 50.66M
52-week range
BCYC stock today
On Nov 20, BCYC ended the session at $2.90, shedding $0.15 (4.92%), versus the S&P 500's 3.70% decline. Volume was 2.3x the average at 1.02M shares, a sign of unusually heavy trading. Shares are 63.0% below their 52-week high of $7.83, set on Nov 28, 2025 and 1.8% above the 52-week low of $2.85, near the bottom of the past year's range.
BCYC is down 59.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 54.1%. Bicycle Therapeutics has posted a net loss over the last twelve months (EPS of -$2.03), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Bicycle Therapeutics
Company profileBicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Kevin Lee M.B.A., Ph.D.
- Headquarters
- Cambridge
- Employees
- 288
- IPO year
- 2019
- Website
- bicycletherapeutics.com
Financial highlights
Full financialsIn fiscal 2025, Bicycle Therapeutics generated $72.6 million in revenue, up 105.8% from fiscal 2024, its 5th consecutive year of revenue growth. Bicycle Therapeutics reported a net loss of $219.0 million, compared with a loss of $169.0 million a year earlier. Operating margin was -340.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $72.59M | $35.27M | $26.98M | $14.46M | $11.70M |
| Growth | +105.77% | +30.76% | +86.52% | +23.65% | +12.58% |
| Net income | $-218.96M | $-169.03M | $-180.66M | $-112.72M | $-66.82M |
| EPS (diluted) | $-3.16 | $-2.90 | $-5.08 | $-3.80 | $-2.67 |
Analyst forecast
ForecastConsensus (9 analysts)
buy
Avg. price target
$9.17+216.21%
- Strong buy 2
- Buy 4
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 29, 2026
- EPS actual vs est.
- $-0.15 vs $-0.30
- Surprise
- +50.00%
BCYC news
All BCYC newsBicycle Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| FTHFaeth Therapeutics Inc. | 7.88 | -9.32% | $203.65M | vs BCYC |
| DRUGBright Minds Biosciences Inc. | 20.40 | -1.45% | $201.23M | vs BCYC |
| NGENNervGen Pharma Corp. | 1.85 | -3.91% | $198.55M | vs BCYC |
| VNDAVanda Pharmaceuticals Inc. | 3.45 | -6.13% | $208.32M | vs BCYC |
| BIOABioAge Labs Inc. | 4.28 | -9.13% | $196.67M | vs BCYC |
| YARWYarrow Bioscience Inc. | 12.90 | -9.35% | $196.53M | vs BCYC |
| CYPHCypherpunk Technologies Inc. | 1.41 | -18.02% | $210.15M | vs BCYC |
| ACIUAC Immune SA | 1.95 | -8.45% | $193.88M | vs BCYC |
Indexes, lists and sector
Bicycle Therapeutics stock FAQ
What is Bicycle Therapeutics's stock price today?
BCYC last traded at $2.90 as of Nov 20, 4:00 PM EST, down 4.92% on the day. Prices are delayed at least 15 minutes.
Who is Bicycle Therapeutics's CEO?
Dr. Kevin Lee M.B.A., Ph.D. is the chief executive officer of Bicycle Therapeutics plc ADR, which has about 288 employees.
What is the BCYC 52-week high?
The 52-week high for BCYC is $7.83 and the 52-week low is $2.85. The stock is currently 63.0% below its high.